Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phentermine is a sympathomimetic amine and appetite suppressant used as a short-term adjunct in the management of obesity. It is typically prescribed for individuals who are overweight or obese and have not achieved sufficient weight loss with diet and exercise alone. Phentermine acts primarily by stimulating the central nervous system to increase norepinephrine release in the lateral hypothalamus, which suppresses appetite. It may also increase dopamine levels and weakly affect serotonin reuptake. The drug was first introduced in 1959 and remains one of the most commonly prescribed anti-obesity medications. Phentermine is available as oral tablets or capsules under several brand names[1][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phentermine.